Victor Perlroth, M.D.

New Capabilities

As of September 2026: Leading Kodiak toward its first FDA filing

A drug Kodiak Sciences shelved in 2023 after a cataract safety signal is now on track for an FDA filing. The company reported Monday that both its experimental therapies for wet age-related macular degeneration met their primary endpoints against Regeneron's standard-of-care Eylea in the Phase 3 DAYBREAK trial.

Updated Sep 29